8 completed, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 14 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 8, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Severe Hypertriglyceridemia: new trials by email Literature Review of Severe Hypertriglyceridemia trials Research Report on Severe Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule, Matching Placebo Subcutaneous Injection - Severe Hypertriglyceridemia | Phase 3 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 378 | 2026-08-01 | 2026-07-06 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis Plozasiran, Placebo - Severe Hypertriglyceridemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 288 | 2025-04-24 | 2026-09-21 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 311 | 2024-07-23 | 2026-10-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 446 | 2024-07-22 | 2026-10-08 |
| To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | 89bio, Inc. | 369 | 2023-06-15 | 2026-07-07 |
| CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Olezarsen - Severe Hypertriglyceridemia | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 885 | 2022-12-13 | 2025-12-01 |
| A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 446 | 2022-08-31 | 2025-10-22 |
| A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 617 | 2021-10-25 | 2026-02-10 |
| Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL Placebo, MAT9001 (omega-3 pentaenoic acid) - Severe Hypertriglyceridemia | Phase 3 | Withdrawn | Matinas Biopharma, Inc | 2021-06-01 | 2021-09-16 | |
| Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia | Phase 3 | Completed | Kowa Research Institute, Inc. | 551 | 2016-11-28 | 2022-11-30 |
| Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia | Phase 3 | Completed | Kowa Research Institute, Inc. | 471 | 2016-11-26 | 2022-10-28 |
| Epanova® for Lowering Very High Triglycerides placebo, omefas - Severe Hypertriglyceridemia | Phase 2 / Phase 3 | Completed | AstraZeneca | 399 | 2011-01-01 | 2016-08-04 |
| Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia AKR-963 - Severe Hypertriglyceridemia | Phase 3 | Unknown | Trygg Pharma, Inc. | 240 | 2010-10-01 | 2011-11-24 |
| The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL) Placebo, SC401B 2 capsules, SC401B 4 capsules - Severe Hypertriglyceridemia | Phase 3 | Withdrawn | Sancilio and Company, Inc. | 2016-11-25 |
Hypertriglyceridemia (14) · Hyperlipidemias (4) · Dyslipidemias (3) · Metabolic Diseases (3) · Lipid Metabolism Disorders (1)
Nutritional and Metabolic Diseases (14) · Lipid Metabolism Disorders (13) · Dyslipidemias (11) · Metabolic Diseases (11) · Hyperlipidemias (10)
olezarsen (3) · plozasiran (3) · Fenofibrate (2) · K-877 compound (2) · MAT9001 (1) · eicosapentaenoic acid ethyl ester (1)
Arrowhead Pharmaceuticals (3) · Ionis Pharmaceuticals, Inc. (3) · Kowa Research Institute, Inc. (2) · 89bio, Inc. (1) · AstraZeneca (1) · Matinas Biopharma, Inc (1) · Sancilio and Company, Inc. (1) · Trygg Pharma, Inc. (1) · Zhejiang Doer Biologics Co., Ltd. (1)
United States (11) · Hungary (10) · Bulgaria (9) · Czechia (9) · Poland (8) · Canada (7) · Argentina (6) · Slovakia (6) · Spain (6) · Belgium (5) · Brazil (5) · France (5) · Italy (5) · United Kingdom (5) · Georgia (4)
Kevin C Maki, PhD (2) · Jianping Li (1) · Judith Johnson (1) · Linong Ji (1) · Michael H Davidson, MD, FACC (1) · Teresa Parli, MD (1)
PMID 40064331, PMID 41211918, PMID 24528690
2023 (3)